The Parker Model:Applying a Qualitative Three-Step Approach to Optimally Utilize Input from Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases by Jørgensen, Tanja S et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
The Parker Model
Jørgensen, Tanja S; Skougaard, Marie; Taylor, Peter C; Asmussen, Hans C; Lee, Anne;
Klokker, Louise; Svejstrup, Louise; Mountian, Irina; Gudbergsen, Henrik; Kristensen, Lars
Erik
Published in:
The Patient
DOI:
10.1007/s40271-018-0306-8
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC
Citation for published version (APA):
Jørgensen, T. S., Skougaard, M., Taylor, P. C., Asmussen, H. C., Lee, A., Klokker, L., ... Kristensen, L. E.
(2018). The Parker Model: Applying a Qualitative Three-Step Approach to Optimally Utilize Input from
Stakeholders When Introducing New Device Technologies in the Management of Chronic Rheumatic Diseases.
The Patient, 11(5), 515-526. https://doi.org/10.1007/s40271-018-0306-8
Download date: 03. Feb. 2020
ORIGINAL RESEARCH ARTICLE
The Parker Model: Applying a Qualitative Three-Step Approach
to Optimally Utilize Input from Stakeholders When Introducing
New Device Technologies in the Management of Chronic
Rheumatic Diseases
Tanja S. Jørgensen1 • Marie Skougaard1 • Peter C. Taylor2 • Hans C. Asmussen3 •
Anne Lee4 • Louise Klokker1 • Louise Svejstrup5 • Irina Mountian6 •
Henrik Gudbergsen1 • Lars Erik Kristensen1
Published online: 11 June 2018
 The Author(s) 2018
Abstract
Background and Objective Qualitative methods such as
semi-structured interviews and focus-groups are used to
evaluate the applicability and relevance of device tech-
nologies in clinical practice, but when used alone, often
lack generalizability. This study aimed to assess the face
validity and feasibility of using a composite, three-step
qualitative method (the Parker Model), to inform the
development and implementation of ava, an electrome-
chanical device (e-Device) for subcutaneous self-
administration of the biologic, certolizumab pegol (CZP),
used to treat rheumatic diseases.
Methods The Parker Model combines concept mapping
(CM), participatory design (PD), and stakeholder evalua-
tion (SE). CM, a structured group process, was used to
identify patients’ opinions and concerns regarding the
e-Device. Patients used this information in iterative PD
sessions to create personal e-Device prototypes in coop-
eration with a designer and a healthcare professional. SE
was performed based on semi-structured group and indi-
vidual interviews with patients and disease-management
stakeholders.
Results The study recruited 14 patients, two doctors, two
nurses, one medical secretary, and four other public ser-
vants. Three CM workshops revealed four key considera-
tions: technical usability, physical design, concerns, and
enthusiasm. Four personalized prototypes were developed
during PD sessions. SE confirmed that the identified con-
siderations were pivotal for the implementation and adap-
tation of the e-Device.
Conclusions This study is the first to apply a composite,
qualitative research model when introducing an e-Device
for the treatment and management of rheumatic disease.
Results show that input from patients and other stake-
holders using the Parker Model can add value to the
development and implementation of an e-Device.
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article (https://doi.org/10.1007/s40271-018-0306-8) contains supple-
mentary material, which is available to authorized users.
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Key Points for Decision Makers
The Parker Model is a composite, qualitative
research model designed to evaluate the
development and implementation of new medical
device technologies.
The Parker Model combines three distinct
methodologies (concept mapping, participatory
design, and stakeholder evaluation) which support
the flow of information between participants, helping
to elucidate key themes influencing user responses to
new device technologies.
This study used a new electromechanical self-
injection device (e-Device) to face validate the
Parker Model. Feedback from patients and other key
stakeholders demonstrated that the model
comprehensively captured all constraining concepts
related to the device’s design and use, generated
feasible solutions to overcome these constraints, and
was associated with patients reporting high levels of
empowerment.
1 Introduction
Biologic agents, such as tumor necrosis factor-a inhibitors
(anti-TNFs), have emerged as important, effective thera-
peutics for many chronic inflammatory conditions,
including rheumatoid arthritis (RA), psoriatic arthritis
(PsA) and ankylosing spondylitis (AS) [1–3]. The efficacy
and safety of anti-TNF therapeutics are the principal fac-
tors affecting both patients’ experience and treatment
outcomes. However, other treatment-related characteristics
also influence patient satisfaction and their compliance and
persistence (adherence) to treatment [4]. For example,
biologic agents are often self-injected, but this can be
difficult for patients with rheumatic disease, which is often
associated with reduced dexterity [5, 6].
Adherence to therapy is suboptimal across multiple
chronic conditions including rheumatic diseases [4], cre-
ating a significant barrier to achieving therapeutic out-
comes [7]. The introduction of new technologies for the
management of chronic conditions, which effectively meet
patients’ needs, may advance patient engagement and
empowerment, and improve adherence to long-term treat-
ment [8]. To achieve this, end-user perspectives need to be
considered during device development and implementa-
tion. Currently, widely diverging methods are used to
assess end-user perspectives, including combinations of
focus groups, semi-structured interviews, and ethnographic
studies [9]. Standardizing the methods used to obtain end
user feedback on the use and design of new medical
devices would help ensure consistent and effective end-
user involvement in the development and implementation
of medical devices.
The objective of the current study was to evaluate the
face validity and feasibility of the Parker Model—a novel,
composite, qualitative research approach—as a method of
assessing end-user perspectives on new self-injection
device technologies. The Parker Model is a three-step,
synergistic process comprising concept mapping (CM),
participatory design (PD), and stakeholder evaluation (SE)
which explores the applicability and relevance of intro-
ducing the new technology in real-life clinical practice.
Here, we describe and evaluate the use of the Parker Model
in the implementation of ava, a reusable, electronic
device (e-Device) for self-injecting single-use, disposable,
pre-filled dose-dispenser cartridges of certolizumab pegol
(CZP) [an anti-TNF approved for the treatment of RA,
PsA, and axial spondyloarthritis (axSpA)] [10]. CM was
used to identify the core concepts underlying patients’
thoughts on the e-Device design and functionality. PD took
the insights gained during the CM and investigated how the
device could be further adapted to meet individual patient
needs. SE was used to gather insights from patients and key
disease-management stakeholders to inform the imple-
mentation and future development of the e-Device.
2 Methods
2.1 Patients and Eligibility
Patients receiving CZP treatment were recruited from the
Department of Rheumatology, Copenhagen University
Hospital, Bispebjerg and Frederiksberg, Denmark. To be
eligible to participate, patients had to be aged 18–85 years,
diagnosed with moderate to severe RA, or spondyloarthritis
(SpA) (split into PsA and AS). Patients were consecutively
recruited from the outpatient clinic to participate in the
Parker Model until qualitative data saturation (defined as
the presence of redundancy in emerging concepts) was
achieved. If data saturation was not achieved after the first
three CM sessions were run, two additional sessions would
be run.
Prior to the first CM session, all participants attended a
meeting where they were provided with the e-Device,
instructions for use and a dummy dose-dispenser cartridge
to familiarize themselves with the design (Fig. 1). To
ensure each participant understood the design features of
the e-Device, a trained instructor explained how the
e-Device would be used by patients. No simulated injec-
tions were performed, but the patients were allowed to
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practice and explore the injection process with the e-De-
vice using a reusable dose-dispenser cartridge that did not
contain a needle, syringe or any medication.
All procedures were performed in accordance with the
ethical standards of the responsible committee on human
experimentation (institutional and national) and with the
Helsinki Declaration of 1964, as revised in 2013. Informed
consent was obtained from all patients before being
included in the study, and the project was approved by the
Regional Ethical Committee (file number: 16016608).
2.2 The Parker Model
The Parker model was developed and conducted at the
Parker Institute, Copenhagen F, Denmark between
November 2016 and January 2017 and comprises three
qualitative methods: CM, PD, and SE (Fig. 2). The meth-
ods were selected so that information could be easily
transferred between each component of the study, ensuring
no insights were lost.
Fig. 1 The ava e-Device:
contents of the ava kit (a); key
features of ava (b). The ava
kit comes in a storage case with
the ava device, a user manual,
a welcome booklet giving an
introduction to and overview of
ava, a help line contact card to
assist patients with any
questions or concerns they may
have about ava, an electrical
charger (including regional
plug), 2 spare needle caps
(green), a USB/micro USB
cable, and a reusable dose-
dispenser cartridge that does not
contain a needle, syringe or any
medication, which allows
patients to practice and explore
the injection process. e-Device
electromechanical device
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The CM involved full-day, patient group workshops to
capture the main concepts underpinning patients’ thoughts
regarding a hypothetical switch from CZP treatment by
self-injection using a pre-filled syringe (PFS) to self-ad-
ministration using an e-Device. The concepts identified in
the CM workshops were used in three iterative, full-day PD
sessions to develop personalized prototypes of an e-Device
that patients felt was ‘ideal’ and met their individual needs.
Finally, SE was conducted via interviews with patients who
were unable to participate for the full-day CM and PD
workshops, and key disease-management stakeholders, to
explore the applicability and relevance of implementing the
e-Device.
2.2.1 Concept Mapping
CM is a formal group process with a structured approach
used to identify and organize ideas on a topic of interest. It
is highly effective for the development of outcome mea-
sures, such as key patient considerations, when using a
device for the first time [11]. In this study, CM was con-
ducted through three, full-day, focus groups with patients
with RA or SpA. At the start of each focus group the CM
process was introduced and directed as detailed in Sup-
plementary Figure 1 [see the Electronic Supplementary
Material (ESM)]. For more detailed information on the CM
methodology please refer to the ‘Supplementary Methods.’
Clustering analysis was performed on the participant
statements generated during the three focus group CM
workshops using multidimensional scaling (MDS) analysis
(CS Global MAX; Concept Systems, Inc.) [12]. The x and
y values from the MDS were used to perform a hierarchical
cluster analysis which divided the statements into non-
overlapping clusters [13, 14]; any duplicate statements
within the concept maps were removed [11, 15]. Inde-
pendent and thematic analysis of the reduced statement
pool were performed separately by two authors (L. Klokker
and T.S. Jørgensen), to identify common clusters while
preserving both the exact wording of the statements and the
cluster labels assigned to them by patients during the
workshop (described in Supplementary Figure 1).
To identify which issues were most important for
patients with rheumatic disease treated with biologics,
patients were asked to rate the importance of each state-
ment on a 5-point scale, from 1 (‘not important’ for people
with RA or PsA receiving biologics) to 5 (‘very impor-
tant’). Mean and median ratings of importance assigned by
the patients for each statement were calculated using
Wilcoxon two-sample test.
2.2.2 Participatory Design
Patients who participated in the CM workshops and self-
injected CZP using a PFS were invited to participate in
three iterative PD sessions to investigate how the device
could be further adapted to meet individual patient needs.
Patients were asked to use the PD sessions to ‘develop an
ideal device’ based on their specific individual needs and
the concepts identified in the CM workshops. Each PD
session took the form of a non-structured interview of *
70 min duration. A healthcare professional (HCP) (T.S.
Jørgensen) and a product designer (H.C. Asmussen) were
present at all sessions to act as consultants to the patients.
At the beginning of each PD session the designer pre-
sented the current state of development; for session 1, this
was the original e-Device. At the end of each PD work-
shop, the patient and designer agreed to a set of key find-
ings identified during the session. Using these findings and
any patient sketches, the device designer then produced a
device prototype using paper and clay. The prototype was
presented to the patient at the beginning of the consecutive
session for their feedback, which was then used to itera-
tively improve the subsequent version of the prototype. At
the end of the third session, the patient was presented with
a 3D rendered image of the final version of their prototype.
A total of four prototypes (one for each participant) were
produced.
2.2.3 Stakeholder Evaluation
SE evaluated the applicability and relevance of introducing
the e-Device, using a combination of individual and group
interviews with key disease-management stakeholders and
patients. Disease management stakeholders from within the
Department of Rheumatology, the Regional Clinical
Pharmacological Department, and the Regional Service
Center for Research and Innovation were recruited by
Fig. 2 The Parker Model used to gain stakeholder input on the design
and implementation of ava. Concept mapping and participatory
design were used to gather the patients’ perception of the relevance of
the e-Device, and stakeholder evaluation provided a broader
perspective of both the relevance and the implementation of the
e-Device through the engagement of healthcare professionals,
healthcare managers, a device specialist and an economist, in addition
to patients. e-Device electromechanical device
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email invitation. Patients eligible for the study who were
unable to participate in the full-day CM workshops were
recruited for the SE.
Topics of discussion in the SE interviews included dri-
vers and barriers regarding the standard route of injection
(PFS) versus the e-Device, and how various elements of the
e-Device could be adapted or improved in the next gen-
eration of the e-Device to better meet patients’ needs.
The interviews were guided and analyzed using theory-
based SE, which utilized three theories [16]. Situation
theory was used to examine how stakeholders perceived
the design features of the e-Device compared with the PFS,
understand how the e-Device would be implemented in
clinical practice, and identify any perceived challenges
with the device’s implementation. Normative theory was
used to evaluate stakeholders’ values, ideals, and goals
with regard to introducing and implementing the e-Device.
Causal theory was used to examine stakeholder’s opinions
on how an e-Device would directly or indirectly impact
(either positively or negatively) current challenges and
values associated with the PFS.
A transcript of each interview was produced. The tran-
scripts were assessed to identify any comments related to
current practice, ideals for practice, and how the e-Device
might impact on these issues. Statements in each interview
transcript were grouped into themes and coded accordingly
[17, 18]. The sections of the transcript text marked with the
same theme code across all interviews were compiled and
read with the aim of interpreting the meaning of, and
identifying any differences between, stakeholder
statements.
2.3 Patient-Reported Outcome Measures
To support the face validation and feasibility of the Parker
Model as well as investigate the impact of being part of the
project, following completion of the workshops, patients
were asked to complete a questionnaire that included three
validated instruments, translated into Danish: the Health
Education Impact Questionnaire (heiQ), to evaluate patient
education and empowerment [19–22]; the Service User
Technology Acceptability Questionnaire (SUTAQ), to
assess the acceptability of technology in general [23]; and
the e-Health Literacy Questionnaire (eHLQ), to assess
health literacy, such as the patient’s motivation and ability
to engage with digital technologies [24, 25]. A detailed
summary of the content of each questionnaire is provided
in the ‘Supplementary Methods.’
Individual item scores were based on the Likert scales:
1–4 for both heiQ and eHLQ, and 1–6 for SUTAQ. For all
scales, high values indicate positive health-related out-
comes, except for the ‘emotional distress’ item in heiQ,
where higher values mean greater emotional distress, and
for ‘privacy and discomfort’ and ‘care personnel concerns’
in SUTAQ, for which a high score reflects a high level of
concern. Descriptive statistical analyses were used to report
the results from the questionnaires.
All analyses were carried out using Stata, version 14
[26]. Results from the questionnaire are presented as mean
scores.
3 Results
A total of 56 patients were invited to participate in the
study. Of those 21 did not reply to the invitation and 21
declined to participate. Of the 14 patients who took part
(seven male and seven female), nine had RA, four had PsA,
and one had AS. Other stakeholders included two doctors,
two nurses, one medical secretary, and four other public
servants involved in the management of the selected
rheumatic diseases.
3.1 Concept Mapping
CM was applied to three focus group workshops: two
groups with four patients with RA in each, and one group
with four PsA patients. Patients had a mean age of
65.3 years (min–max: 49–76) and a mean disease duration
of 10.8 years (7–23).
During the CM workshops, 121 patient statements were
generated and analyzed using cluster analyses; four key
concepts emerged regarding e-Device implementation,
which were reviewed by all workshop participants: tech-
nical usability, physical design, concerns, and enthusiasm.
The four concepts (clusters), sub-clusters, and examples of
statements that fell into each cluster/sub-cluster, are shown
in Table 1. Homogenous response, also known as ‘satura-
tion,’ was achieved; this indicated that the number of
patients included was sufficient and so the option to expand
the number of CM workshops was not used.
Each participant also rated the statement’s relative
importance with respect to patients receiving treatment
using the e-Device. Participants rated ‘easy to use,’ ‘the
main function is to take the medication’ and ‘must be easy
to handle when you have sore fingers,’ as being the most
important statements (Supplementary Figure 2; see the
ESM). In contrast, ‘it’s hard to imagine how the needle is
positioned in the device,’ ‘sharing information with the
doctor can feel like being monitored,’ and ‘must be capable
of handling flexible doses’ were rated as being of relatively
minor importance (Supplementary Figure 2).
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3.2 Participatory Design
Three male and one female patient (two with RA and two
with PsA; mean age: 66.8 years; min–max: 54–76) who
had participated in the CM workshops were recruited to
individually participate in three iterative PD sessions each.
The patients’ brief was to use the three PD sessions to
create a prototype that they felt would be an ideal e-Device
that met their individual needs, whilst also bearing in mind
all the concepts identified in the CM workshops. A number
of key design features of the e-Device were highlighted by
patients as being important during the PD sessions,
including the size and shape, sound, the screen, connec-
tivity options, charging options, and portability. A sum-
mary of the PD session discussions, and the 3D rendered
images of the final personalized prototypes developed by
the designer after the final PD session, are provided in
Table 2.
3.3 Stakeholder Evaluation
To reduce the impact of power dynamics [27], SE com-
prised two group interviews (one with HCPs, the other with
patients) and four individual interviews. The HCP group
interview was conducted with two physicians, two nurses
and one medical secretary from the department of
rheumatology at the same hospital; the patient group
interview was conducted with one male patient with RA
and one female patient with AS. Solo interviews were
conducted with the head of a clinical pharmacological
department and member of RADS (the Danish council for
the use of expensive hospital medicines), a chief nurse, and
an economist (both the nurse and economist were at the
management level in hospital rheumatology departments),
and a regional medical and innovation consultant.
Analysis of the interview transcripts indicated two major
themes: everyday life (with flexibility and functionality
identified as sub-themes) and, relevance and clinical
practice (with compliance and time as sub-themes). The
drivers and barriers associated with the implementation and
use of the standard route of injection [PFS and pre-filled
pen (PFP)] and the e-Device, and how various elements
could be adapted and developed in the current and next
generation of the e-Device, were discussed (Table 3). In
general, the results of the SE interviews highlighted broad
Table 1 Concepts produced from patient statements regarding the e-Device in the concept mapping workshops
Concepts (clusters) Sub-clusters Patient statements
Design and handling of the device Manageability (simple)
Size of the device
The needle
Easy to use/simple set-up
Easier to handle than the syringe
Too clumsy/too big (should look more like a pen)
The needle should be thinner than it is now
An advantage that the needle is not visible
Technical features and additional
equipment
Keep it simple
Software for wireless
communication
Setting of the device (flexibility
important)
Cooling system (when travelling)
Reminder, calendar, diary, etc.
Main function: take the medication
Remote communication between patient and doctor/hospital
Flexibility
Communication with tablets and smart phones
Use the device for other type of medication (e.g., methotrexate)
Concerns Will it be too much trouble?
The device is not for everybody
The device makes me dependent
Testing of the device
Data security
Makes me independent/not flexible to the life I live
Too much control
I do not want to be controlled by the device
Difficult for persons unfamiliar with IT
Is there support, if needed urgently?
Has it been tested on patients? (The device/needle is placed
differently on the skin)
Sharing of data needs to be voluntary
Enthusiasm Very useful
Safety
Very helpful for those who do not like needles
Helpful for people with finger problems
It can easily be used as it is now
I do not have to worry about getting all the medication
e-Device electromechanical device
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Table 2 Central findings and prototypes produced from PD sessions with patients
Central findings from the PD sessions with the patient Patient prototypes
Patient 1 (male, 54 years)
User does not like needles; the concept of ‘ava’ is well received
Ergonomic considerations; optional 3D-printed gripping area a possibility
Comments on screen angle; needs to be based on practical use. User puts screen flat on device for
increased visibility while injecting. User would not inject in thigh—injecting into abdominal area
seems ‘easier’ to the user
Tool reference; e-Device needs a quality feel—like a ‘good’ tool
Device must be identifiable as a medical device/tool
Patient 2 (male, 76 years)
No issues with needles—syringe is simple/ideal and is user controlled; doesn’t like automated systems
Existing device seems to require force in use due to bulky design
Wireless communication with clinic would be valuable
Ergonomic considerations
No need for a screen; haptic or audio-based feedback is enough
Use and design must be as simple as possible—device cannot complicate use
Patients must expect to be checked up on by the clinic—they receive expensive medication and proper
use should be ensured
Novel loading concept created—resembling a bullet loading mechanism
Technology should be used to simplify things—not to complicate the users’ life
Every patient has his own way of taking the medication
The sound of the ‘ava’ isn’t good; the user feels like he is being stabbed upon motor-start
Cooling options for transport are discussed
User is ‘happy to be of help to others’
If a riffle-like loading system is implemented, it is important that patients with gripping problems can
use the system
The final product must ‘speak’ to the patients in the right way
Product needs to be self-diagnosing
Patient 3 (male, 66 years)
Syringe is ideal—if the needle is covered
Simplicity and ease of use are central points
User has no problems with the sharing of data with clinic
Flexible reminder system, text message, push or other solution suitable for a range of platforms
The ‘ava’ is ‘overkill’ (quote in relation to design). It is pleasant to hold, though
Design must be smaller, simpler and slimmer
All users have personal rituals for the use of their medication
Flexible splitting of screen and pen creates a range of user scenarios
Electrical toothbrush is used as an example of a ‘buzzer’ interface
Aesthetics are important—as is ease of use
Induction charging, the spilt elements and travelling/cooling options would all contribute to the
flexibility of use
User referenced the sharing economy—travelling/cooling options could be shared by users and booked
online
Vision impaired users and the advantages of non-visual feedback should be considered
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differences in the types of perspectives shared by the dif-
ferent groups; patients were more focused on the func-
tionality of the device and making suggestions relevant to
incorporating the technology into everyday life, whilst key
disease-management stakeholders were more focused on
injection logging and the associated data compliance, time-
saving considerations for patients and HCPs, the types of
patients and treatment scenarios for which the e-Device
would be relevant, and implementation of the e-Device in
clinical practice.
3.4 Patient-Reported Outcomes
After participating in the evaluation on the e-Device, all 14
participating patients were invited to complete a ques-
tionnaire which included heiQ, SUTAQ and eHLQ to
assess the participants’ health literacy, the levels of
empowerment they felt regarding the e-Device and their
acceptance of technology in general. A total of seven male
and five female patients (86%) responded; demographic
characteristics of the respondents are shown in Supple-
mentary Table 1 (see the ESM). The results of the heiQ,
SUTAQ, and eHLQ are shown in Supplementary Figure 3.
While the patients who evaluated the e-Device and
responded to the questionnaires had medium-high health
literacy (based on feedback from the heiQ), the e-Device
was associated with high levels of empowerment, and there
were high levels of acceptability of e-Device technology
(in general) among the group.
4 Discussion
The aim of this study was to assess the face validity and
feasibility of the Parker Model at acquiring end-user per-
spectives on new self-injection device technologies. The
Parker Model used a synergistic three-step qualitative
method incorporating CM, PD, and SE, which was devel-
oped to inform the design, development, and implementa-
tion of a new e-Device for the subcutaneous self-
administration of CZP in patients with rheumatic disease.
Unstructured feedback collected from all participants at the
end of the study demonstrated that they thought the Parker
model comprehensively captured all constraining concepts
related to the device’s design and use, and the model
effectively generated feasible solutions to overcome all
identified constraints; as such, the Parker Model method
was regarded highly relevant for its purpose.
The results of the CM and PD phases of the study indi-
cated that while the introduction of the e-Device for the
disease management of chronic rheumatic diseases is a
welcome development, no single e-Device design would be
ideal for all patients—‘no size fits all.’ However, providing
patients with a number of different injection device options
to choose from would enable them to select an option suited
to their needs. Overall, the Parker Model evaluation suggests
that by carefully considering the feedback on the design,
function, and implementation of the e-Device raised by
patients and disease-management stakeholders, their
expectations and requirements can be met through informed
implementation and improvement of the e-Device.
The Parker Model methodology of using CM, PD, and
SE has several advantages over using any one of these
methods individually. Used together, these methods inter-
act and support the flow of information from one session to
the next, helping to mediate a co-creative process involving
participants and investigators. The Parker method also has
advantages over other qualitative research methods that are
used in the development and implementation of medical
devices. Ethnographic studies are field based analyses and
so have the advantage of observing patients in a ‘real
world’ setting [28]; however, they are associated with
investigator interpretation bias [29], and they are resource
intensive, limiting the number of participants and
Table 2 continued
Central findings from the PD sessions with the patient Patient prototypes
Patient 4 (female, 71 years)
The ‘ava’ is big, clumsy and heavy—the design makes this user ‘feel worse’
Good if smartphone could be used for reminders
Syringe is an ideal solution
Design needs to be elegant—‘if I’m going to have to live with this—it needs to look good’
Very slim first prototype facilitates delicate grip
Active user—long-lasting cooling solution needed for travel; up to 72 h of off-grid use for overseas
travelling
Customs and cargo handling of device should be considered
An active cooling solution could ease anxiety with the user when collecting medication
Hand impaired users should be considered
e-Device electromechanical device, PD participatory design
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Table 3 Perspectives identified by SE of the applicability and relevance of introducing an e-Device to self-administer CZP for patients with
rheumatic diseases
Key stakeholder perspectives and suggestions identified through SE interviews
Functionality of the e-Device
All stakeholders: the e-Device is ergonomic, fits well in the palm of the hand, easy to handle, yet relatively large. They found the dose
dispenser cartridge easy to manage, though large when including the needle cap
Head nurse: device good for patients with arthritis; useful to have all equipment in one bag; relatively large bag is an issue for portability
HCPs: good display—letters are easy to read; offer the choice of different languages
Head nurse and patients: the reminder function is an advantage in the upstart phase
HCPs: concern that patients might find injection logging to be unwelcome monitoring
Patients: not concerned by injection logging since they already keep a record of their injections
HCPs: the non-visible needle is an advantage for patients afraid of needles
All stakeholders: other advantages are securing skin contact before an injection, automated injection, and choice of injection speed
Patients: satisfied with the standard route of CZP administration; the e-Device needs to offer more before they would consider changing
All stakeholders: why is the device for one medicine only? RADS member: it would be advantageous if the e-Device could be used to
administer other medications, especially those with known poor compliance
Patients and the economist: unmet need is the dispenser cartridge having capacity for multiple doses. This would allow patients to take more
doses at a time, reducing the frequency of hospital visits
Patient: no need for the device to tell you that the medication and the dose he is to administer are correct as only one medication and a
particular dose can be administered with the device
Patient: relying on the e-Device would ‘take away my empowerment’
Patient: access to the standard route of CZP administration is a necessary back-up in case of e-Device failure
Patient: battery power option would be convenient for portability and use while travelling
Head nurse: unmet need for patient information with FAQs, including who to contact if the device fails, and illustrations for patients who
cannot read, and translation of the materials into Danish
Flexibility
Stakeholders: unmet need is flexibility in terms of the timing of injections. Most patients are experienced and capable of administering their
medication on a schedule that best suits them. The patients stressed the importance of this flexibility to feel empowered in relation to their
disease and treatment. A suggested solution was to set up the e-Device with slots of a few days for injections instead of fixed dates
HCPs: concerned that patients would need a hospital visit to adjust the device in case of a dose change, which would be time-consuming for
both patients and HCPs. Suggestion: remote set-up of the e-Device, through an electronic connection between the e-Device and the hospital
Head nurse: patients might not remember to bring the e-Device to consultations when needed. Suggestion: incorporating a cooling bag for the
medication into the storage case for the device
Logging of data and compliance
HCPs: the injection log may be helpful for patients who forget to take their medication, adding to treatment safety, and the option to use the
injection log in consultations with the patient is an advantage
Economist: incorporating the injection log into the hospital databases would be an advantage for combining other information about the
patient with their injection log, and for organizational and research purposes
RADS member: the injection log would be valuable for research and treatment decision-making (being able to compare compliance and
treatment efficacy)
Patients: happy to share the injection log with HCPs because it would provide the HCP with the best information for decision-making; they
are dependent on the HCP
Time saving for patients and HCPs
HCPs: the e-Device would be easy for patients to learn, but would not save time for nurses, who would need to instruct each patient on how to
use the e-Device. More time may need to be spent by both the patient and the HCP if the patient forgets to bring the e-Device to
consultations and additional consultations are required as a result. The potential need for a physician to be present during a nurse
consultation in the case of a change in dose, this would result in extra time consumption for the physician
Incorporating technology into everyday life
HCPs: the e-Device should be able to communicate with the electronic systems already used in hospitals
Patients: the reminder system would only be useful if it was available on electronic devices that they use every day, not on the e-Device itself,
which they turn on only to inject. The patients preferred the ability to connect to tablets and smartphones, over computers. They considered
wireless connection to be modern, and connection by cable to be old-fashioned. Electronic communication between the home and hospital
to transfer information would be valuable and would save on hospital visits
Head nurse: suggested a secure Danish website for sharing health information between the hospital and home; the option to remotely change
the dose on the e-Device would be an advantage
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generalizability of the data [28]. Semi-structured inter-
views provide the flexibility required for participants to
give varied and personal responses, but also capture
heterogeneous opinions that are difficult to generalize.
The Parker Model increased the generalizability of the
CM results by using a focus-group format and a nominal
group process [30], which gave each participant the
opportunity to provide input (preventing more outspoken
participants from dominating the discussion). This, and the
CM process itself, ensured a variety of perspectives, while
also reducing the number of clustered statements because
participants were asked to identify the key concepts toge-
ther [31]. The Parker Model further increased generaliz-
ability by ensuring that all participants involved in the PD
session had also participated in the CM session. This
helped to ensure that the prototypes developed during this
session incorporated the feedback from all patients. The SE
broadened the focus to include stakeholder input on the
context of the e-Device and future iterations of it in the
current healthcare setting, to evaluate device eligibility for
implementation and how to make it readily beneficial in the
public setting. Practically, since the three steps of the
Parker Model can be applied in parallel, it is also an effi-
cient way of capturing the various inputs from patients and
other stakeholders.
High levels of treatment adherence among multiple
sclerosis patients have been reported in studies examining
the use of electronic injection devices that are similar to the
e-Device evaluated in the current study; for example,
allowing patients to individually adjust settings, such as
injection speed and depth, and having the ability to elec-
tronically store data such as date and time of injections
[32–34]. Consistent with these studies in multiple sclerosis,
patients with rheumatic diseases recruited to provide their
input on the e-Device in the current study reported high
levels of e-Device acceptability and high levels of
empowerment in the heiQ, SUTAQ, and eHLQ question-
naire. Patient engagement in healthcare is associated with
better treatment adherence, which has the potential to
improve health outcomes and patient care, and reduce
treatment costs [35, 36]. Patients’ desire for empowerment
was previously reported in an ethnographic study exploring
contrasts in patient- and physician-reported views on living
with RA [37], which, together with the results from the
current study, suggests that ava has the potential to
improve patient engagement, which may improve treat-
ment adherence.
The main limitations of the current study were associ-
ated with the relatively small number of patients and dis-
ease-management stakeholders, who were all from the
Table 3 continued
Key stakeholder perspectives and suggestions identified through SE interviews
For which patients and treatment scenarios will an e-Device be relevant?
All stakeholders: not relevant for patients happy with self-injection via the standard route, but the e-Device might be introduced as a choice to
patients starting CZP treatment
Member of RADS: the e-Device is relevant for patients not able to self-inject via the standard route
Head nurse: the e-Device is relevant for compliant patients, those able to handle their medication from home, and patients who are familiar
with electronics to some extent or are not afraid of it
Head nurse and economist: there is economic potential in switching patients who require either assistance with self-injection, or
administration by infusion, to the e-Device; the member of RADS disagreed: switching patients receiving medication by infusion would not
reduce contact time
Implementation of an e-Device in clinical practice
The economist, member of RADS, and HCPs: decisions regarding the choice of primary treatment prescribed to newly diagnosed patients are
made at a national level; if the price of the e-Device was the same as for the standard route of CZP administration, then patient preferences
and the injection log may be good arguments for the use of the e-Device
Member of RADS: advantages of the e-Device are not sufficient to recommend CZP as the primary treatment if more expensive than the
alternative and the efficacy and adverse effect profiles are comparable
Member of RADS: a generic e-Device for the sole purpose of creating and injection log might save the healthcare system money because the
injection log would allow non-compliant patients to be identified and would prevent those patients being switched to more expensive
treatments
Head nurse: a concern is that the Danish accounting system is based on the number of hospital visits; implementing an e-Device would not be
an incentive in a Danish hospital if it saves visits
The medical and innovation consultant: there are issues regarding data sharing, which requires approval by the health authorities, and the IT
departments must be consulted early for the e-Device to be compliant with data security. Data management needs to be thoroughly
described, including who owns the data, how will the data be shared, where and how will the data be stored, and who has access. If data are
to be shared with and used in clinical practice, the data also need to be in a form compatible with the IT systems already in use
CZP certolizumab pegol, e-Device electromechanical device, HCP healthcare professional, RADS the Danish council for the use of expensive
hospital medicines, SE stakeholder evaluation
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same healthcare setting; stakeholder input from various
institutions would have furthered the generalizability of the
results. The small number of patients limited the range of
ages that could be surveyed, and the patients were not all
being treated for the same rheumatic disease, which may
have introduced heterogeneity in the results. The male-to-
female ratio among the recruited patients was equal, which
is not representative of the fact that some rheumatic dis-
eases affect more females than males. The patients also had
established disease, meaning that they were already
accustomed to, and satisfied with, self-injection using the
PFS or PFP, and had sufficient dexterity and hand function
to operate the e-Device. No patients had to be excluded
from the study due to being unable to use the device;
however, the patients recruited in this study may not be
representative of all patients with rheumatic disease, and
no one device design is likely to be ‘ideal’ for all patients.
5 Conclusions
Overall, this study has demonstrated that the Parker Model
is an effective qualitative method for collecting and gen-
eralizing responses from patients and other key stake-
holders involved in disease management. This is the first
time a composite, qualitative research model has been
applied when introducing a new device to support the
treatment of rheumatic diseases, and these resources can
help ensure added value when developing devices for
disease management. Although this study only evaluated
the Parker Model in the context of a self-injection device,
with further testing the model could also be applied to
evaluate other medical devices, app technologies, and
communication strategies; as such, the Parker Model has
the potential to play a pivotal role in the future of per-
sonalized and outcome-based disease management models
in a range of chronic disease areas.
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